RadNet Competitors

Burning Rock Biotech (NASDAQ:BNR) and RadNet (NASDAQ:RDNT) are both business services companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, dividends, earnings, valuation and risk.

Profitability

This table compares Burning Rock Biotech and RadNet's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Burning Rock Biotech and RadNet's revenue, earnings per share and valuation.

RadNet has higher revenue and earnings than Burning Rock Biotech.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Burning Rock Biotech and RadNet, as reported by MarketBeat.

Burning Rock Biotech currently has a consensus price target of $32.30, indicating a potential downside of 10.25%. RadNet has a consensus price target of $22.50, indicating a potential upside of 22.02%. Given RadNet's higher possible upside, analysts plainly believe RadNet is more favorable than Burning Rock Biotech.

Institutional and Insider Ownership

15.8% of Burning Rock Biotech shares are held by institutional investors. Comparatively, 67.5% of RadNet shares are held by institutional investors. 5.8% of RadNet shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Fulgent Genetics (NASDAQ:FLGT) and RadNet (NASDAQ:RDNT) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, dividends, earnings, valuation and risk.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Fulgent Genetics and RadNet, as reported by MarketBeat.

Fulgent Genetics currently has a consensus price target of $73.40, indicating a potential downside of 27.51%. RadNet has a consensus price target of $22.50, indicating a potential upside of 22.02%. Given RadNet's stronger consensus rating and higher possible upside, analysts plainly believe RadNet is more favorable than Fulgent Genetics.

Risk & Volatility

Fulgent Genetics has a beta of 1.92, meaning that its stock price is 92% more volatile than the S&P 500. Comparatively, RadNet has a beta of 1.52, meaning that its stock price is 52% more volatile than the S&P 500.

Institutional and Insider Ownership

33.4% of Fulgent Genetics shares are held by institutional investors. Comparatively, 67.5% of RadNet shares are held by institutional investors. 45.0% of Fulgent Genetics shares are held by company insiders. Comparatively, 5.8% of RadNet shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Fulgent Genetics and RadNet's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Fulgent Genetics and RadNet's revenue, earnings per share and valuation.

RadNet has higher revenue and earnings than Fulgent Genetics. RadNet is trading at a lower price-to-earnings ratio than Fulgent Genetics, indicating that it is currently the more affordable of the two stocks.

Summary

Fulgent Genetics beats RadNet on 7 of the 13 factors compared between the two stocks.

RadNet (NASDAQ:RDNT) and Genetron (NASDAQ:GTH) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, dividends, earnings and risk.

Analyst Ratings

This is a breakdown of current ratings and target prices for RadNet and Genetron, as reported by MarketBeat.com.

RadNet currently has a consensus price target of $22.50, indicating a potential upside of 22.02%. Genetron has a consensus price target of $19.50, indicating a potential downside of 20.70%. Given RadNet's higher possible upside, research analysts clearly believe RadNet is more favorable than Genetron.

Institutional & Insider Ownership

67.5% of RadNet shares are held by institutional investors. Comparatively, 19.6% of Genetron shares are held by institutional investors. 5.8% of RadNet shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares RadNet and Genetron's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares RadNet and Genetron's revenue, earnings per share and valuation.

RadNet has higher revenue and earnings than Genetron.

Summary

RadNet beats Genetron on 5 of the 9 factors compared between the two stocks.

RadNet (NASDAQ:RDNT) and Castle Biosciences (NASDAQ:CSTL) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, dividends, earnings and risk.

Analyst Ratings

This is a breakdown of current ratings and target prices for RadNet and Castle Biosciences, as reported by MarketBeat.com.

RadNet currently has a consensus price target of $22.50, indicating a potential upside of 22.02%. Castle Biosciences has a consensus price target of $73.80, indicating a potential downside of 3.00%. Given RadNet's higher possible upside, research analysts clearly believe RadNet is more favorable than Castle Biosciences.

Risk & Volatility

RadNet has a beta of 1.52, meaning that its share price is 52% more volatile than the S&P 500. Comparatively, Castle Biosciences has a beta of 0.46, meaning that its share price is 54% less volatile than the S&P 500.

Institutional & Insider Ownership

67.5% of RadNet shares are held by institutional investors. Comparatively, 66.4% of Castle Biosciences shares are held by institutional investors. 5.8% of RadNet shares are held by insiders. Comparatively, 39.7% of Castle Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares RadNet and Castle Biosciences' net margins, return on equity and return on assets.

Earnings and Valuation

This table compares RadNet and Castle Biosciences' revenue, earnings per share and valuation.

RadNet has higher revenue and earnings than Castle Biosciences. Castle Biosciences is trading at a lower price-to-earnings ratio than RadNet, indicating that it is currently the more affordable of the two stocks.

Summary

RadNet beats Castle Biosciences on 9 of the 13 factors compared between the two stocks.

RadNet (NASDAQ:RDNT) and DermTech (NASDAQ:DMTK) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, dividends, earnings and risk.

Analyst Ratings

This is a breakdown of current ratings and target prices for RadNet and DermTech, as reported by MarketBeat.com.

RadNet currently has a consensus price target of $22.50, indicating a potential upside of 22.02%. DermTech has a consensus price target of $50.25, indicating a potential downside of 24.70%. Given RadNet's higher possible upside, research analysts clearly believe RadNet is more favorable than DermTech.

Risk & Volatility

RadNet has a beta of 1.52, meaning that its share price is 52% more volatile than the S&P 500. Comparatively, DermTech has a beta of 0.99, meaning that its share price is 1% less volatile than the S&P 500.

Institutional & Insider Ownership

67.5% of RadNet shares are held by institutional investors. Comparatively, 51.4% of DermTech shares are held by institutional investors. 5.8% of RadNet shares are held by insiders. Comparatively, 16.5% of DermTech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares RadNet and DermTech's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares RadNet and DermTech's revenue, earnings per share and valuation.

RadNet has higher revenue and earnings than DermTech. DermTech is trading at a lower price-to-earnings ratio than RadNet, indicating that it is currently the more affordable of the two stocks.

Summary

RadNet beats DermTech on 9 of the 13 factors compared between the two stocks.

RadNet (NASDAQ:RDNT) and Personalis (NASDAQ:PSNL) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, dividends, earnings and risk.

Analyst Ratings

This is a breakdown of current ratings and target prices for RadNet and Personalis, as reported by MarketBeat.com.

RadNet currently has a consensus price target of $22.50, indicating a potential upside of 22.02%. Personalis has a consensus price target of $39.3333, indicating a potential upside of 27.58%. Given Personalis' higher possible upside, analysts clearly believe Personalis is more favorable than RadNet.

Risk & Volatility

RadNet has a beta of 1.52, meaning that its share price is 52% more volatile than the S&P 500. Comparatively, Personalis has a beta of 1.71, meaning that its share price is 71% more volatile than the S&P 500.

Institutional & Insider Ownership

67.5% of RadNet shares are held by institutional investors. Comparatively, 65.5% of Personalis shares are held by institutional investors. 5.8% of RadNet shares are held by insiders. Comparatively, 8.2% of Personalis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares RadNet and Personalis' net margins, return on equity and return on assets.

Earnings and Valuation

This table compares RadNet and Personalis' revenue, earnings per share and valuation.

RadNet has higher revenue and earnings than Personalis. Personalis is trading at a lower price-to-earnings ratio than RadNet, indicating that it is currently the more affordable of the two stocks.

Summary

RadNet beats Personalis on 8 of the 14 factors compared between the two stocks.